In other words, VPA and WT161 showed the same trend in regulating APP, BACE1, and PS-1 expression and the opposite trend in regulating ADAM10 expression, but both could reduce the concentration of soluble Aβ42 in AD cell models. The gene discussed is ADAM10; the disease is Alzheimer disease.